

# CLINICAL TRIAL

NIGHT

Research



## Natural History of the Progression of Choroideremia Study NSR-CHM-OS1

Rare Eye Disease concerned by the trial :  
Choroideremia

Status of the trial : recruiting  
Orphan drug recognition : Yes

**Inclusion criteria :** Patients are willing and able to provide informed consent for participation in the study, are male and  $\geq 18$  years of age, have a clinical phenotype and confirmed genetic diagnosis of CHM, have active disease clinically visible within the macular region, are willing and able to undergo ophthalmic examinations once every 4 months for up to 20 months, have a BCVA better than or equal to 6/60 in at least one eye (see Section 7.1 for more information)

**Exclusion criteria :** [click here to see detailed criteria](#)



**Inclusion opening date :** 08/08/2017



**Inclusion closing date (previsional) :** 31/12/2018

Children



Adults



### Within ERN-EYE members



**Principal location of the trial :**

**Center for Ophthalmic Research, University Hospital of Tübingen**

Elfriede-Aulhorn-Str. 7  
72076 Tübingen  
Germany

[Contact details](#)



**Principal investigator name :**

Prof. Dr. Dr. Dominik Fischer



**Other investigators :**


**University Hospital of Tübingen**

Tübingen, Germany

*Prof. Dr. med. Karl Ulrich Bartz-Schmidt*

**Radboud University Medical Center,**

Nijmegen, Netherlands



**Funder type :** Drug company - Industry

[More informations](#)